{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:10:47Z","timestamp":1794964247311,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Monoclonal antibodies (mAbs) and remdesivir, a small-molecule antiviral, are promising monotherapies for many viruses, including members of the genera <jats:italic>Marburgvirus<\/jats:italic> and <jats:italic>Ebolavirus<\/jats:italic> (family <jats:italic>Filoviridae<\/jats:italic>), and more recently, SARS-CoV-2. One of the major challenges of acute viral infections is the treatment of advanced disease. Thus, extending the window of therapeutic intervention is critical. Here, we explore the benefit of combination therapy with a mAb and remdesivir in a non-human primate model of Marburg virus (MARV) disease. While rhesus monkeys are protected against lethal infection when treatment with either a human mAb (MR186-YTE; 100%), or remdesivir (80%), is initiated 5 days post-inoculation (dpi) with MARV, no animals survive when either treatment is initiated alone beginning 6 dpi. However, by combining MR186-YTE with remdesivir beginning 6 dpi, significant protection (80%) is achieved, thereby extending the therapeutic window. These results suggest value in exploring combination therapy in patients presenting with advanced filovirus disease.<\/jats:p>","DOI":"10.1038\/s41467-021-22132-0","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T11:06:58Z","timestamp":1616670418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Combination therapy protects macaques against advanced Marburg virus disease"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7718-1522","authenticated-orcid":false,"given":"Robert W.","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7557-9219","authenticated-orcid":false,"given":"Zachary A.","family":"Bornholdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-2077","authenticated-orcid":false,"given":"Abhishek N.","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Borisevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-6935","authenticated-orcid":false,"given":"Krystle N.","family":"Agans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Deer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna M.","family":"Abelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Shestowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lioudmila A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Bunyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan B.","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla A.","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-1024","authenticated-orcid":false,"given":"Larry","family":"Zeitlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-2370","authenticated-orcid":false,"given":"Danielle P.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-1877","authenticated-orcid":false,"given":"Thomas W.","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"22132_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrd.2017.251","volume":"17","author":"RW Cross","year":"2018","unstructured":"Cross, R. W., Mire, C. E., Feldmann, H. & Geisbert, T. W. Post-exposure treatments for Ebola and Marburg virus infections. Nat. Rev. Drug Discov. 17, 413\u2013434 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"22132_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000536","volume":"5","author":"JS Towner","year":"2009","unstructured":"Towner, J. S. et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. 5, e1000536 (2009).","journal-title":"PLoS Pathog."},{"key":"22132_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1056\/NEJMoa051465","volume":"355","author":"DG Bausch","year":"2006","unstructured":"Bausch, D. G. et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N. Engl. J. Med. 355, 909\u2013919 (2006).","journal-title":"N. Engl. J. Med."},{"key":"22132_CR4","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1128\/JVI.00069-06","volume":"80","author":"JS Towner","year":"2006","unstructured":"Towner, J. S. et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 80, 6497\u20136516 (2006).","journal-title":"J. Virol."},{"key":"22132_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002877","volume":"8","author":"BR Amman","year":"2012","unstructured":"Amman, B. R. et al. Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog. 8, e1002877 (2012).","journal-title":"PLoS Pathog."},{"key":"22132_CR6","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.3201\/eid1312.071115","volume":"13","author":"R Swanepoel","year":"2007","unstructured":"Swanepoel, R. et al. Studies of reservoir hosts for Marburg virus. Emerg. Infect. Dis. 13, 1847\u20131851 (2007).","journal-title":"Emerg. Infect. Dis."},{"key":"22132_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-159","volume":"9","author":"X Pourrut","year":"2009","unstructured":"Pourrut, X. et al. Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect. Dis. 9, 159 (2009).","journal-title":"BMC Infect. Dis."},{"key":"22132_CR8","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3201\/eid2010.140696","volume":"20","author":"B Amman","year":"2014","unstructured":"Amman, B. et al. Marburgvirus resurgence in Kitaka Mine bat population after extermination attempts, Uganda. Emerg. Infect. Dis. J. 20, 1761 (2014).","journal-title":"Emerg. Infect. Dis. J."},{"key":"22132_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14327-8","volume":"11","author":"BR Amman","year":"2020","unstructured":"Amman, B. R. et al. Isolation of Angola-like Marburg virus from Egyptian rousette bats from West Africa. Nat. Commun. 11, 510 (2020).","journal-title":"Nat. Commun."},{"key":"22132_CR10","doi-asserted-by":"publisher","first-page":"S312","DOI":"10.1093\/infdis\/jix636","volume":"218","author":"K Changula","year":"2018","unstructured":"Changula, K. et al. Seroprevalence of Filovirus Infection of Rousettus aegyptiacus Bats in Zambia. J. Infect. Dis. 218, S312\u2013S317 (2018).","journal-title":"J. Infect. Dis."},{"key":"22132_CR11","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3201\/eid2508.190268","volume":"25","author":"M Kajihara","year":"2019","unstructured":"Kajihara, M. et al. Marburgvirus in Egyptian Fruit Bats, Zambia. Emerg. Infect. Dis. J. 25, 1577 (2019).","journal-title":"Emerg. Infect. Dis. J."},{"key":"22132_CR12","doi-asserted-by":"crossref","unstructured":"Leitenberg, M. & Zilinskas, R. A. The Soviet Biological Weapons Program: A History. (Harvard Univ. Press, 2012).","DOI":"10.4159\/harvard.9780674065260"},{"key":"22132_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.det.2004.03.003","volume":"22","author":"MR Salvaggio","year":"2004","unstructured":"Salvaggio, M. R. & Baddley, J. W. Other viral bioweapons: Ebola and Marburg hemorrhagic fever. Dermatol. Clin. 22, 291\u2013302 (2004).","journal-title":"Dermatol. Clin."},{"key":"22132_CR14","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1073\/pnas.1200409109","volume":"109","author":"JM Dye","year":"2012","unstructured":"Dye, J. M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl Acad. Sci. USA 109, 5034\u20135039 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22132_CR15","doi-asserted-by":"publisher","first-page":"13467","DOI":"10.1128\/JVI.01896-12","volume":"86","author":"M Kajihara","year":"2012","unstructured":"Kajihara, M. et al. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J. Virol. 86, 13467\u201313474 (2012).","journal-title":"J. Virol."},{"key":"22132_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","volume":"160","author":"AI Flyak","year":"2015","unstructured":"Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of marburg virus. Cell 160, 893\u2013903 (2015).","journal-title":"Cell"},{"key":"22132_CR17","doi-asserted-by":"publisher","unstructured":"Mire, C. E. et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aai8711 (2017).","DOI":"10.1126\/scitranslmed.aai8711"},{"key":"22132_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.chom.2017.12.003","volume":"23","author":"LB King","year":"2018","unstructured":"King, L. B. et al. The Marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding. Cell Host Microbe 23, 101\u2013109 e104 (2018).","journal-title":"Cell Host Microbe"},{"key":"22132_CR19","doi-asserted-by":"publisher","first-page":"S662","DOI":"10.1093\/infdis\/jiy235","volume":"218","author":"A Marzi","year":"2018","unstructured":"Marzi, A., Haddock, E., Kajihara, M., Feldmann, H. & Takada, A. Monoclonal antibody cocktail protects Hamsters from lethal Marburg virus infection. J. Infect. Dis. 218, S662\u2013S665 (2018).","journal-title":"J. Infect. Dis."},{"key":"22132_CR20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.chom.2020.03.025","volume":"27","author":"PA Ilinykh","year":"2020","unstructured":"Ilinykh, P. A. et al. Non-neutralizing antibodies from a Marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies. Cell Host Microbe 27, 976\u2013991 e911 (2020).","journal-title":"Cell Host Microbe"},{"key":"22132_CR21","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1172\/JCI96185","volume":"127","author":"EP Thi","year":"2017","unstructured":"Thi, E. P. et al. siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease. J. Clin. Invest. 127, 4437\u20134448 (2017).","journal-title":"J. Clin. Invest."},{"key":"22132_CR22","doi-asserted-by":"publisher","first-page":"250ra116","DOI":"10.1126\/scitranslmed.3009706","volume":"6","author":"EP Thi","year":"2014","unstructured":"Thi, E. P. et al. Marburg virus infection in nonhuman primates: therapeutic treatment by lipid-encapsulated siRNA. Sci. Transl. Med. 6, 250ra116 (2014).","journal-title":"Sci. Transl. Med"},{"key":"22132_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1570163810666131120150043","volume":"11","author":"WR Strohl","year":"2014","unstructured":"Strohl, W. R. Antibody discovery: sourcing of monoclonal antibody variable domains. Curr. Drug Disco. Technol. 11, 3\u201319 (2014).","journal-title":"Curr. Drug Disco. Technol."},{"key":"22132_CR24","doi-asserted-by":"publisher","first-page":"G47","DOI":"10.1016\/j.vaccine.2009.10.124","volume":"27","author":"JE Crowe Jr","year":"2009","unstructured":"Crowe, J. E. Jr Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches. Vaccine 27, G47\u2013G51 (2009).","journal-title":"Vaccine"},{"key":"22132_CR25","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/infdis\/jit119","volume":"207","author":"SA Smith","year":"2013","unstructured":"Smith, S. A. et al. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J. Infect. Dis. 207, 1898\u20131908 (2013).","journal-title":"J. Infect. Dis."},{"key":"22132_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.chom.2015.06.009","volume":"18","author":"SA Smith","year":"2015","unstructured":"Smith, S. A. et al. Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against Chikungunya virus. Cell Host Microbe 18, 86\u201395 (2015).","journal-title":"Cell Host Microbe"},{"key":"22132_CR27","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1126\/science.aad5788","volume":"351","author":"ZA Bornholdt","year":"2016","unstructured":"Bornholdt, Z. A. et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351, 1078\u20131083 (2016).","journal-title":"Science"},{"key":"22132_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00101-16","author":"PA Ilinykh","year":"2016","unstructured":"Ilinykh, P. A. et al. Chimeric filoviruses for identification and characterization of monoclonal antibodies. J. Virol. https:\/\/doi.org\/10.1128\/JVI.00101-16 (2016).","journal-title":"J. Virol."},{"key":"22132_CR29","doi-asserted-by":"publisher","first-page":"14701","DOI":"10.1073\/pnas.0606631103","volume":"103","author":"A Giritch","year":"2006","unstructured":"Giritch, A. et al. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc. Natl Acad. Sci. USA 103, 14701\u201314706 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22132_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381\u2013385 (2016).","journal-title":"Nature"},{"key":"22132_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa290","author":"DP Porter","year":"2020","unstructured":"Porter, D. P. et al. Remdesivir (GS-5734) is efficacious in cynomolgus macaques infected with Marburg virus. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiaa290 (2020).","journal-title":"J. Infect. Dis."},{"key":"22132_CR32","doi-asserted-by":"publisher","first-page":"eaau9242","DOI":"10.1126\/scitranslmed.aau9242","volume":"11","author":"MK Lo","year":"2019","unstructured":"Lo, M. K. et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci. Transl. Med. 11, eaau9242 (2019).","journal-title":"Sci. Transl. Med."},{"key":"22132_CR33","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1073\/pnas.1922083117","volume":"117","author":"E de Wit","year":"2020","unstructured":"de Wit, E. et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl Acad. Sci. USA 117, 6771\u20136776 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22132_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2423-5","author":"BN Williamson","year":"2020","unstructured":"Williamson, B. N. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature https:\/\/doi.org\/10.1038\/s41586-020-2423-5 (2020).","journal-title":"Nature"},{"key":"22132_CR35","unstructured":"Administration, U. S. F. a. D. FDA approves first treatment for COVID-19 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19 (2020)."},{"key":"22132_CR36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 - Final report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2007764 (2020).","journal-title":"N. Engl. J. Med."},{"key":"22132_CR37","doi-asserted-by":"crossref","unstructured":"Goldman, J. D. et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N. Engl. J. Med. 383, 1827\u20131837 (2020).","DOI":"10.1056\/NEJMoa2015301"},{"key":"22132_CR38","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner, C. D. et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324, 1048\u20131057 (2020).","journal-title":"JAMA"},{"key":"22132_CR39","unstructured":"Administration, U. S. F. a. D. COVID-19 update: FDA broadens emergency use authorization for veklury (remdesivir) to include all hospitalized patients for treatment of COVID-19 https:\/\/www.fda.gov\/news-events\/press-announcements\/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized (2020)."},{"key":"22132_CR40","doi-asserted-by":"publisher","unstructured":"Tchesnokov, E. P., Feng, J. Y., Porter, D. P. & Gotte, M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses https:\/\/doi.org\/10.3390\/v11040326 (2019).","DOI":"10.3390\/v11040326"},{"key":"22132_CR41","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC120.015720","author":"EP Tchesnokov","year":"2020","unstructured":"Tchesnokov, E. P. et al. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J. Biol. Chem. https:\/\/doi.org\/10.1074\/jbc.AC120.015720 (2020).","journal-title":"J. Biol. Chem."},{"key":"22132_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","volume":"25","author":"ZA Bornholdt","year":"2019","unstructured":"Bornholdt, Z. A. et al. A two-antibody pan-Ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates. Cell Host Microbe 25, 49\u201358 e45 (2019).","journal-title":"Cell Host Microbe"},{"key":"22132_CR43","doi-asserted-by":"publisher","first-page":"S372","DOI":"10.1086\/520608","volume":"196","author":"TW Geisbert","year":"2007","unstructured":"Geisbert, T. W. et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J. Infect. Dis. 196, S372\u2013S381 (2007).","journal-title":"J. Infect. Dis."},{"key":"22132_CR44","first-page":"1178122","volume":"10","author":"S Languon","year":"2019","unstructured":"Languon, S. & Quaye, O. Filovirus disease outbreaks: a chronological overview. Virol. 10, 1178122\u201319849927 (2019).","journal-title":"Virol."},{"key":"22132_CR45","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"PIW Group","year":"2016","unstructured":"Group, P. I. W. et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N. Engl. J. Med. 375, 1448\u20131456 (2016).","journal-title":"N. Engl. J. Med."},{"key":"22132_CR46","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293\u20132303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"22132_CR47","doi-asserted-by":"crossref","unstructured":"Cohen, J. Update: here\u2019s what is known about Trump\u2019s COVID-19 treatment. Science https:\/\/www.sciencemag.org\/news\/2020\/10\/heres-what-known-about-president-donald-trump-s-covid-19-treatment (2020).","DOI":"10.1126\/science.abf0974"},{"key":"22132_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17446-4","volume":"11","author":"RW Cross","year":"2020","unstructured":"Cross, R. W. et al. Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment. Nat. Commun. 11, 3736 (2020).","journal-title":"Nat. Commun."},{"key":"22132_CR49","doi-asserted-by":"publisher","first-page":"S582","DOI":"10.1093\/infdis\/jiy293","volume":"218","author":"C Woolsey","year":"2018","unstructured":"Woolsey, C. et al. Postexposure efficacy of recombinant vesicular stomatitis virus vectors against high and low doses of Marburg virus variant Angola in nonhuman primates. J. Infect. Dis. 218, S582\u2013S587 (2018).","journal-title":"J. Infect. Dis."},{"key":"22132_CR50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0168-1702(95)00080-1","volume":"39","author":"TW Geisbert","year":"1995","unstructured":"Geisbert, T. W. & Jahrling, P. B. Differentiation of filoviruses by electron microscopy. Virus Res. 39, 129\u2013150 (1995).","journal-title":"Virus Res."},{"key":"22132_CR51","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1177\/0300985813485099","volume":"50","author":"KN Gibson-Corley","year":"2013","unstructured":"Gibson-Corley, K. N., Olivier, A. K. & Meyerholz, D. K. Principles for valid histopathologic scoring in research. Vet. Pathol. 50, 1007\u20131015 (2013).","journal-title":"Vet. Pathol."},{"key":"22132_CR52","unstructured":"R: a language and environment for statistical computing v. 4.0.2 (R Foundation for Statistical Computing, 2020)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22132-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22132-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22132-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T11:18:44Z","timestamp":1669979924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22132-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["22132"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-22132-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"25 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.A.B., D.M.A., D.H.K., W.S.S., L.A.C., and L.Z. are employees of and shareholders in Mapp Biopharmaceutical, Inc. D.P.P and E.B. are employees and shareholders of Gilead Sciences, Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1891"}}